Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Lurasidone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 8/20 | 1.00 |
| ▸ | HTR2A known ✓ | P28223 | 8/20 | 1.00 |
| ▸ | HTR1A | P08908 | 8/20 | 1.00 |
| ▸ | DRD3 | P35462 | 5/20 | 1.00 |
| ▸ | HTR7 | P34969 | 3/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 2/20 | 1.00 |
| ▸ | HTR2B | P41595 | 2/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 2/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 2/20 | 1.00 |
| ▸ | DRD1 | P21728 | 2/20 | 1.00 |
| ▸ | TBXA2R | P21731 | 2/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 2/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 2/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 2/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 1/20 | 1.00 |
| ▸ | ACHE | P22303 | 1/20 | 1.00 |
| ▸ | PDE4A | P27815 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lurasidone SCHEMBL12620240 | 1.00 | DRD2 (1.00) | DRD2HTR2AHTR1ADRD3HTR7 | |
| Lurasidone SCHEMBL2587434 | 1.00 | DRD2 (1.00) | DRD2HTR2AHTR1ADRD3HTR7 | |
| Lurasidone SCHEMBL677525 | 1.00 | DRD2 (1.00) | DRD2HTR2AHTR1ADRD3HTR7 | |
| Lurasidone SCHEMBL19678283 | 1.00 | DRD2 (1.00) | DRD2HTR2AHTR1ADRD3HTR7 | |
| Lurasidone SCHEMBL15505744 | 1.00 | DRD2 (1.00) | DRD2HTR2AHTR1ADRD3HTR7 | |
| Lurasidone SCHEMBL17982546 | 1.00 | DRD2 (1.00) | DRD2HTR2AHTR1ADRD3HTR7 | |
| Lurasidone SCHEMBL16804108 | 1.00 | DRD2 (1.00) | DRD2HTR2AHTR1ADRD3HTR7 | |
| Lurasidone SCHEMBL10034018 | 1.00 | DRD2 (1.00) | DRD2HTR2AHTR1ADRD3HTR7 | |
| Lurasidone SCHEMBL21702794 | 1.00 | DRD2 (1.00) | DRD2HTR2AHTR1ADRD3HTR7 | |
| Lurasidone SCHEMBL15978832 | 1.00 | DRD2 (1.00) | DRD2HTR2AHTR1ADRD3HTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9469630-B2 | Sustained-release formulation for injection | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2016-10-18 | — | — | US | claimed |
| US-20160158228-A1 | SUSTAINED-RELEASE FORMULATION FOR INJECTION | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2016-06-09 | — | — | US | claimed |
| US-20120091022-A1 | SUSTAINED-RELEASE FORMULATION FOR INJECTION | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2012-04-19 | — | — | US | claimed |
| EP-1327440-B1 | ORAL PREPARATIONS WITH FAVORABLE DISINTEGRATION CHARACTERISTICS | DAINIPPON SUMITOMO PHARMA CO (JP) | 2009-05-13 | — | — | EP | claimed |
| US-20190010149-A1 | SUSTAINED-RELEASE FORMULATION FOR INJECTION | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2019-01-10 | — | — | US | disclosed |
| US-20190010149-A1 | SUSTAINED-RELEASE FORMULATION FOR INJECTION | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2019-01-10 | — | — | US | disclosed |
| US-9469630-B2 | Sustained-release formulation for injection | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2016-10-18 | — | — | US | disclosed |
| US-9469630-B2 | Sustained-release formulation for injection | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2016-10-18 | — | — | US | disclosed |
| US-20160158228-A1 | SUSTAINED-RELEASE FORMULATION FOR INJECTION | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2016-06-09 | — | — | US | disclosed |
| US-20160158228-A1 | SUSTAINED-RELEASE FORMULATION FOR INJECTION | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2016-06-09 | — | — | US | disclosed |
| US-20140206667-A1 | METHODS AND COMPOSITIONS FOR TREATING SCHIZOPHRENIA | THE JOHNS HOPKINS UNIVERSITY | 2014-07-24 | — | — | US | disclosed |
| JP-2013543481-A | — | — | 2013-12-05 | — | — | JP | disclosed |
| EP-2629775-A1 | SUSTAINED-RELEASE FORMULATION FOR INJECTION | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2013-08-28 | — | — | EP | disclosed |
| CN-103249416-A | Sustained-release preparation for injection | DAINIPPON SUMITOMO PHARMA CO | 2013-08-14 | — | — | CN | disclosed |
| WO-2012053654-A1 | SUSTAINED-RELEASE FORMULATION FOR INJECTION | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-04-26 | — | — | WO | disclosed |
| US-20120091022-A1 | SUSTAINED-RELEASE FORMULATION FOR INJECTION | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2012-04-19 | — | — | US | disclosed |
| US-20120091022-A1 | SUSTAINED-RELEASE FORMULATION FOR INJECTION | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2012-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140206667-A1 | METHODS AND COMPOSITIONS FOR TREATING SCHIZOPHRENIA | RAB2A, SYNGR2, GRIN2A | DRD2 901/4885HTR2A 5/4885HTR1A 179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.